Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the systemic treatment of triple-negative breast cancer.

Current oncology (Toronto, Ont.) - 1 Jun 2018

Lebert J M, Lester R, Powell E, Seal M, McCarthy J

Abstract excerpt

Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Capecitabine
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Medical Oncology

Share to Neoadjuvant Therapy

Share to Paclitaxel

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29910657
DOI: 10.3747/co.25.3954
PMCID: PMC6001760

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the systemic treatment of triple-negative breast cancer.PMID 29910657Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].Semantic proximity Read ↗

Targeted Therapies for Triple-Negative Breast Cancer.Semantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.